Medicare spending analysis for Hematology-Oncology providers
Hematology-Oncology accounts for $22.7B in Medicare payments across 66.9K providers.
The specialty's average markup of 3.5x is below the overall Medicare average of 3.77x.
AI-generated analysis based on Medicare payment data.
Providers in this specialty flagged by the ML v2 fraud detection model
| Year | Payments | Services | Providers | YoY Change |
|---|---|---|---|---|
| 2016 | $2.7B | 252.2M | 8.0K | — |
| 2017 | $2.8B | 246.3M | 8.2K | +3.3% |
| 2018 | $3.0B | 256.6M | 8.2K | +6.7% |
| 2019 | $3.0B | 269.8M | 8.3K | +2.7% |
| 2020 | $2.8B | 247.8M | 8.4K | -7.0% |
| 2021 | $2.9B | 242.2M | 8.5K | +1.1% |
| 2022 | $2.7B | 228.6M | 8.6K | -3.9% |
| 2023 | $2.8B | 214.6M | 8.7K | +1.8% |
| # | Provider | State | Payments | Services | Avg/Service |
|---|---|---|---|---|---|
| 1 | Vinh-Linh Nguyen | CA | $11.5M | 383.7K | $29.91 |
| 2 | Luke Dreisbach | CA | $9.8M | 824.6K | $11.94 |
| 3 | John Waples | AL | $9.6M | 542.6K | $17.76 |
| 4 | Guangzhi Qu | MS | $9.1M | 551.7K | $16.45 |
| 5 | Bassam Mattar | KS | $7.2M | 571.9K | $12.64 |
| 6 | Mei Tang | MD | $6.9M | 426.9K | $16.25 |
| 7 | Justin Kucinski | MD | $6.9M | 294.8K | $23.48 |
| 8 | Jamal Misleh | DE | $6.8M | 379.8K | $17.97 |
| 9 | Dennis Moore | KS | $6.7M | 394.1K | $17.13 |
| 10 | Pavan Reddy | KS | $6.7M | 394.9K | $16.98 |
| 11 | Ravi Rao | CA | $6.6M | 547.8K | $12.02 |
| 12 | David Portnoy | TN | $6.5M | 336.8K | $19.37 |
| 13 | David Smith | MD | $6.4M | 413.7K | $15.42 |
| 14 | Richard Cherny | NY | $6.3M | 449.0K | $13.96 |
| 15 | Christopher Lobo | FL | $6.1M | 507.7K | $12.07 |
| 16 | Syed Zafar | FL | $6.0M | 371.8K | $16.13 |
| 17 | Kamal Patel | AR | $5.7M | 453.8K | $12.54 |
| 18 | Jeremy Deutsch | KS | $5.7M | 301.0K | $18.84 |
| 19 | Andrew Lipman | FL | $5.6M | 436.2K | $12.87 |
| 20 | Dexter Estrada | CA | $5.6M | 546.9K | $10.16 |
| 21 | Hemant Sindhu | AZ | $5.4M | 422.0K | $12.90 |
| 22 | Sachin Gupta | CA | $5.3M | 520.7K | $10.15 |
| 23 | Tammy Young | MS | $5.1M | 334.4K | $15.20 |
| 24 | Anil Potti | ND | $4.9M | 548.5K | $8.95 |
| 25 | Richard Huslig | MD | $4.9M | 555.5K | $8.80 |
| Code | Description | Payments | Services | Avg/Service |
|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | $813.5M | 19.1M | $42.59 |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | $268.3M | 3.1M | $87.30 |
| J0897 | Injection, denosumab, 1 mg | $225.1M | 12.3M | $18.26 |
| J9144 | Injection, daratumumab, 10 mg and hyaluronidase-fihj | $158.4M | 4.2M | $37.62 |
| J9299 | Injection, nivolumab, 1 mg | $145.6M | 6.2M | $23.34 |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | $138.3M | 1.1M | $123.66 |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | $78.1M | 764.4K | $102.18 |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | $73.1M | 1.2M | $60.65 |
| J1569 | Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg | $43.3M | 1.2M | $35.61 |
| 78815 | Nuclear medicine study from skull base to mid-thigh with ct scan | $38.3M | 33.6K | $1.1K |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | $38.1M | 393.6K | $96.80 |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | $34.2M | 220.2K | $155.20 |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | $31.2M | 13.3M | $2.35 |
| J1568 | Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg | $30.9M | 931.5K | $33.13 |
| J1439 | Injection, ferric carboxymaltose, 1 mg | $28.0M | 32.1M | $0.87 |
| J1437 | Injection, ferric derisomaltose, 10 mg | $27.6M | 1.7M | $16.47 |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | $26.6M | 416.4K | $63.90 |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | $20.7M | 149.1K | $138.49 |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | $19.6M | 392.3K | $49.95 |
| J0885 | Injection, epoetin alfa, (for non-esrd use), 1000 units | $19.5M | 3.4M | $5.80 |
Last Updated: February 2026 (data through 2023, the latest CMS release)
Note: All data is from publicly available Medicare records. OpenMedicare is an independent journalism project not affiliated with CMS.